Nalirinox Neo-pancreas RAS Mut ctDNA Study

Clinical trial NCT04010552 · UNKNOWN

Trial details

NCT number: NCT04010552
Sponsor: Fundación de investigación HM
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Resectable Pancreatic Ductal Adenocarcinoma

Start date: 2019-05-01
Primary completion: 2023-08-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.